glp 1 rebound Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression GLP-1 Rebound Prevention: How to

Future research should improve diagnostic criteria and include more diverse populations

Modern GLP-1 receptor agonists have demonstrated average weight loss of 15-20% of body weight with sustained treatment, representing a breakthrough in obesity pharmacotherapy that approaches the effectiveness of bariatric surgery

"Despite the progress we've made in diabetes management, people living with type 2 diabetes often need additional treatments as their condition progresses

Meanwhile, Eli Lilly has told The Pharmaceutical Journal that its next wave of research would be focused on the potential of tailoring therapies to patient subgroups through biomarkers and precision medicine to understand who benefits most from each mechanism